UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2018

Colfax Corporation

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-34045

(Commission File Number) 54-1887631

(I.R.S. Employer Identification No.)

420 National Business Parkway, 5th Floor Annapolis Junction, MD 20701 (Address of Principal Executive Offices) (Zip Code)

(301) 323-9000

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On May 3, 2018, Colfax Corporation issued a press release reporting financial results for the first quarter ended March 30, 2018. A copy of Colfax Corporation's press release is attached to this report as Exhibit 99.1 and is incorporated in this report by reference. Colfax Corporation has scheduled a conference call for 8:00 a.m. Eastern on May 3, 2018 to discuss its financial results.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Colfax Corporation press release dated May 3, 2018, reporting financial results for the first quarter ended March 30, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 3, 2018

Colfax Corporation

By:	/s/ Christopher M. Hix
Name:	Christopher M. Hix
Title:	Senior Vice President, Finance,
	Chief Financial Officer and Treasurer

EXHIBIT INDEX

99.1 Colfax Corporation press release dated May 3, 2018, reporting financial results for the first quarter ended March 30, 2018.

COLFAX

Colfax Reports First Quarter 2018 Results

- Achieved net income per diluted share of \$0.22 from continuing operations and adjusted net income per share of \$0.48 versus \$0.39 in the prior year
- Grew sales 20% or 5% excluding acquisitions and FX
- Completed the acquisition of the Sandvik welding wire business
- Improved full year adjusted net income per share outlook

ANNAPOLIS JUNCTION, MD - May 3, 2018 - Colfax Corporation (NYSE: CFX), a leading diversified industrial technology company, today announced its financial results for the first quarter of 2018.

The Company reported first quarter 2018 net income of \$25 million or \$0.20 per diluted share compared to \$39 million or \$0.31 per diluted share in the prior year quarter. Income from continuing operations was \$27 million or \$0.22 per diluted share, including a \$15 million loss on short term investments and \$8 million of restructuring charges. Adjusted net income in the first quarter was \$60 million, or \$0.48 per share compared to \$48 million or \$0.39 per share for the same prior year period. Results include a \$0.03 gain from a facility sale.

First quarter 2018 net sales of \$881 million grew 20.1% versus the comparable period of 2017, including the impact of acquisitions and foreign currency translation effects (FX). Excluding acquisitions and FX, Fabrication Technology segment sales grew 6.4%, and Air & Gas Handling segment sales increased 2.4%. First quarter 2018 Air & Gas Handling orders decreased 2.5% to \$327 million compared to the prior year period. Excluding acquisitions and FX, orders decreased 24.9%. Air & Gas Handling finished the quarter with backlog of \$889.5 million compared to \$867.2 million at the same time in 2017.

"We delivered another quarter of organic sales growth this quarter, led by solid performance in our Fabrication Technology business," said Matthew Trerotola, President and Chief Executive Officer. "Market demand continues to strengthen in most of this segment's global markets, and we are using CBS to drive further productivity improvements and advance a range of growth initiatives. This segment's margins sequentially improved and were in-line with our expectations for full-year improvement. Our Air & Gas Handling business achieved another quarter of general industrial order growth while continuing to execute restructuring projects to address lower demand for power market applications."

During the first quarter, the Company completed its acquisition of the welding wire operations of Sandvik Materials Technology into its Fabrication Technology segment. Sandvik is a leading provider of stainless steel and nickel alloy filler metal and extends Colfax's portfolio in the faster-growing specialty filler metal segment.

"Colfax is well-positioned to achieve expectations for earnings growth of at least 18% in 2018," said Mr. Trerotola. "We continue to expect overall organic sales growth supported by our faster-growing Fabrication Technology business and improving Air & Gas Handling market conditions later in the year. Restructuring actions are on target to deliver at least \$25 million of savings in 2018, and we have a clear path to margin improvement. Recently-completed acquisitions are performing well and building momentum, and our pipeline of opportunities remains full."

Reflecting first quarter performance, Colfax increased its adjusted earnings per share outlook for the year from \$2.00-\$2.15 to \$2.05-\$2.20.

Conference Call and Webcast

Colfax will host a conference call to provide details about its results today at 8:00 a.m. Eastern. The call will be open to the public through +1-877-303-7908 (U.S. callers) or +1-678-373-0875 (international callers) and referencing the conference ID number 6599567 or through webcast via Colfax's website at www.colfaxcorp.com under the "Investors" section. Access to a supplemental slide presentation can also be found at the Colfax website under the same heading. Both the audio of this call and the slide presentation will be archived on the website later today and will be available until the next quarterly call.

About Colfax Corporation

Colfax Corporation is a leading diversified industrial technology company that provides air & gas handling and fabrication technology products and services to customers around the world principally under the Howden and ESAB brands. Colfax believes that its brands are among the most highly recognized in each of the markets that it serves. The Company uses its Colfax Business System (CBS), a comprehensive set of tools, processes and values, to create superior value for customers, shareholders and associates. Colfax is traded on the NYSE under the ticker "CFX." Additional information about Colfax is available at www.colfaxcorp.com.

Non-GAAP Financial Measures and Other Adjustments

Colfax has provided in this press release financial information that has not been prepared in accordance with GAAP. These non-GAAP financial measures are adjusted net income, adjusted net income per share, projected adjusted net income per share, adjusted operating income, organic sales growth, and organic order decline. Adjusted operating income excludes Restructuring and other related items, gain or loss on short term investments, Goodwill and intangible asset impairment charge and Pension settlement loss. Adjusted net income, adjusted net income per share and projected adjusted net income per share exclude Restructuring and other related charges, gain or loss on short term investments, Goodwill and intangible asset impairment charge, pension settlement loss, acquisition-related intangibles amortization, and other non-cash acquisition related charges. The effective tax rates used to calculate adjusted net income and adjusted net income per share was 21.1% for the first quarter ended March 30, 2018. The effective tax rates used to calculate adjusted net income and adjusted net income per share was 26.0% for the first quarter ended March 31, 2017. Organic sales growth and organic order decline exclude the impact of acquisitions and foreign exchange rate fluctuations. These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release.

CAUTIONARY NOTE CONCERNING FORWARD LOOKING STATEMENTS

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission including its 2017 Annual Report on Form 10-K under the caption "Risk Factors." In addition, these statements are based on a number of assumptions that are subject to change. This press release speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

The term "Colfax" in reference to the activities described in this press release may mean one or more of Colfax's global operating subsidiaries and/or their internal business divisions and does not necessarily indicate activities engaged in by Colfax Corporation.

Contact:

Kevin Johnson, Vice President Colfax Corporation +1-301-323-9090 investorrelations@colfaxcorp.com

Colfax Corporation Condensed Consolidated Statements of Income Dollars in thousands, except per share data (Unaudited)

		Three Months Ended				
	March 30, 2018			March 31, 2017		
Net sales	\$	000.025	\$	732 630		
	\$	880,925	Э	733,630		
Cost of sales		610,305		493,801		
Gross profit		270,620		239,829		
Selling, general and administrative expense		200,519		174,833		
Restructuring and other related charges	. <u></u>	7,929		4,773		
Operating income		62,172		60,223		
Interest expense		9,588		9,254		
Loss on short term investments		14,719		_		
Income from continuing operations before income taxes		37,865		50,969		
Provision for income taxes		5,986		12,578		
Net income from continuing operations		31,879		38,391		
(Loss) income from discontinued operations, net of taxes		(2,837)		3,096		
Net income		29,042		41,487		
Less: income attributable to noncontrolling interest, net of taxes		4,507		2,945		
Net income attributable to Colfax Corporation		24,535		38,542		
Net income (loss) per share - basic and diluted						
Continuing operations	\$	0.22	\$	0.29		
Discontinued operations	\$	(0.02)	\$	0.02		
Consolidated operations	\$	0.20	\$	0.31		

Colfax Corporation Reconciliation of GAAP to Non-GAAP Financial Measures Amounts in thousands, except per share data (Unaudited)

	Three Months Ended			Ended
	March 30, 2018 March 31, 202			March 31, 2017
Adjusted Net Income and Adjusted Net Income Per Share				
Net income from continuing operations attributable to Colfax Corporation ⁽¹⁾	\$	27,372	\$	35,446
Restructuring and other related charges- pretax		7,929		4,773
Acquisition-related amortization and other non-cash charges- pretax ⁽²⁾		20,681		13,394
Loss on short term investments-pretax		14,719		—
Tax adjustment ⁽³⁾		(11,157)		(5,398)
Adjusted net income from continuing operations	\$	59,544	\$	48,215
Adjusted net income margin from continuing operations		6.8%		6.6%
Weighted-average shares outstanding - diluted		124,081		123,795
Adjusted net income per share continuing operations	\$	0.48	\$	0.39
Net income per share- diluted from continuing operations (GAAP)	\$	0.22	\$	0.29

	Updated Guidance			Previous Guidance			
	 Low High		Low			High	
2018 Earnings Per Share							
Projected net income per share from continuing operations (GAAP)- diluted	\$ 1.22	\$	1.37	\$	1.36	\$	1.51
Restructuring and other related charges- pretax	0.31		0.31		0.28		0.28
Acquisition-related amortization and other non-cash charges- pretax ⁽²⁾	0.60		0.60		0.56		0.56
Loss on short term investments- pretax	0.12		0.12				—
Tax adjustment ⁽³⁾	(0.20)		(0.20)		(0.20)		(0.20)
Projected adjusted net income per share	\$ 2.05	\$	2.20	\$	2.00	\$	2.15

(1) Net income from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income from continuing operations less the income attributable to noncontrolling interest, net of taxes.
(2) Includes amortization of acquired intangibles and fair value charges on acquired inventory.
(3) The effective tax rates used to calculate adjusted net income and adjusted net income per share for the three months ended March 30, 2018 and March 31, 2017, respectively, was 21.1% and 26.0%. The estimated effective tax rate for adjusted net income and adjusted net income per share for the year ended December 31, 2018 is 23-24%.

Colfax Corporation Reconciliation of GAAP to Non-GAAP Financial Measures Dollars in thousands (Unaudited)

		Three Months Ended				
	March 30, 2018			March 31, 2017		
Continuing Operations						
Operating income	\$	62,172	\$	60,223		
Operating income margin		7.1%		8.2%		
Restructuring and other related charges		7,929		4,773		
Adjusted operating income	\$	70,101	\$	64,996		
Adjusted operating income margin		8.0%		8.9%		

Colfax Corporation Change in Sales, Orders and Backlog Dollars in millions (Unaudited)

			Air and Gas Handling					
	Net	t Sales	Orders				Backlog at	Period End
	\$	%		\$	%		\$	%
As of and for the three months ended March 31, 2017	\$ 733.6		\$	335.6		\$	867.2	
Components of Change:								
Existing businesses ⁽¹⁾	36.1	4.9%		(83.5)	(24.9)%		(149.1)	(17.2)%
Acquisitions ⁽²⁾	68.8	9.4%		46.6	13.9 %		101.9	11.8 %
Foreign currency translation	42.4	5.8%		28.4	8.5 %		69.5	8.0 %
	147.3	20.1%		(8.5)	(2.5)%		22.3	2.6 %
As of and for the three months ended March 30, 2018	\$ 880.9		\$	327.1		\$	889.5	

⁽¹⁾ Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume.

⁽²⁾ Represents the incremental sales, orders and order backlog from the acquisition completed in our Air and Gas Handling segment, and incremental sales for acquisitions completed in our Fabrication Technology segment.

Colfax Corporation Condensed Consolidated Balance Sheets Dollars in thousands, except share amounts (Unaudited)

	March 30, 2018		December 31, 2017		
ASSETS					
CURRENT ASSETS:					
Cash and cash equivalents	\$	268,346	\$	262,019	
Short term investments		134,889		149,608	
Trade receivables, less allowance for doubtful accounts of \$31,767 and \$31,488		993,068		970,199	
Inventories, net		499,493		429,627	
Other current assets		267,431		258,379	
Total current assets		2,163,227		2,069,832	
Property, plant and equipment, net		546,710		552,802	
Goodwill		2,611,999		2,538,544	
Intangible assets, net		1,016,368		1,017,203	
Other assets		540,910		531,316	
Total assets	\$	6,879,214	\$	6,709,697	
LIABILITIES AND EQUITY					
CURRENT LIABILITIES:					
Current portion of long-term debt	\$	6,129	\$	5,766	
Accounts payable		579,283		587,129	
Customer advances and billings in excess of costs incurred		168,745		145,853	
Accrued liabilities		341,321		358,632	
Total current liabilities		1,095,478		1,097,380	
Long-term debt, less current portion		1,122,077		1,055,305	
Other liabilities		820,415		829,748	
Total liabilities		3,037,970		2,982,433	
Equity:					
Common stock, \$0.001 par value; 400,000,000 shares authorized; 123,477,735 and 123,245,827 issued and outstanding		123		123	
Additional paid-in capital		3,236,334		3,228,174	
Retained earnings		876,177		846,490	
Accumulated other comprehensive loss		(508,077)		(574,372)	
Total Colfax Corporation equity		3,604,557		3,500,415	
Noncontrolling interest		236,687		226,849	
Total equity	-	3,841,244		3,727,264	
Total liabilities and equity	\$	6,879,214	\$	6,709,697	

Colfax Corporation Condensed Consolidated Statements of Cashflows Dollars in thousands (Unaudited)

March 30, 2018 March 31, 2017 Cash flows from operating activities: Net roome \$ 29,042 \$ 41,485 Adjustments to recordle net income to net cash (used in) provided by operating activities: 5,595 5,798 Depreciation, amorization and impairment charges 5,995 5,595 5,798 Non-cash interest expanse 1,120 1,000 Loss on shot term investments (751) (751) Deferred income tas benefit (751) (743) Changes in operating assets and libilities: (7148) (7442) Trade receivables, net (17,896) (1424) Custom shot provided by operating assets and libilities (8100) (7430) Customs dravances and billings in excess of costs incurred (733) (4142) Inventorities, net (733) (4142) Customs dravances and billings in excess of costs incurred (733) (4142) Customs dravances and billings in excess of costs incurred (733) (4142) Proceeds from investing activities (733) (4179) Sale of basines, n			Three Months Ended			
Net income \$ 29,042 \$ 41,433 Adjustments to reconche net income to net cash (used in) provided by operating activities: 36,997 31,977 Deprectation, amortization and impairment charges 36,997 31,977 Stock-based compensation expense 1,120 1,000 Loss on short term investments 14,719 - Deferred income tax benefit (591) (1,423) Gain on sale of facility (7,149) - Charges in operating assets and liabilities: (71,796) (1,424) Trade receivables, net (17,896) (1,424) Inventories, net (17,896) (1,424) Changes in other operating assets and liabilities (30,604) (6,533) Ret cash (used in) provided by operating activities (2,657) (40,402) Changes in other operating activities (2,657) (40,402) Ret cash (used in) provided by operating activities (2,657) (40,402) Proceeds from sile of facility (30,604) - - Set of business, net (11,097) (11,007) (11,007) Proceeds from sile of facility (30,564) -		Ν	March 30, 2018	March 31, 2017		
Adjustments to reconcile net income to net cash (used in) provided by operating activities: 36,987 31,977 Stock-based compensation expense 5,595 5,799 Stock-based compensation expense 1,120 1,000 Loss on short term investments 14,719 — Deferred income tax benefit (591) (1,833) Gain on sale of facility (7,148) — Changes in operating assets and liabilities: (17,896) (1,424) Inventories, net (17,896) (1,424) Customer advances and billings in excess of costs incurred (27,391) (4,912) Changes in other operating assets and liabilities (30,604) (6,338) Changes in other operating assets and liabilities (30,604) (6,338) Changes in other operating assets and liabilities (11,007) (11,007) Changes of fixed assets (11,007) (11,007) (11,007) Purchases of fixed assets (11,007) (11,007) (11,007) Purchases of fixed assets (11,007) (11,007) (11,007) Purchases of fixed assets (10,018) —	Cash flows from operating activities:					
Depreciation, amortization and impairment charges 36,987 31,977 Stock-based compensation expense 5,595 5,798 Non-cash interest expense 1,120 1,000 Loss on short term investments 1,121 1,000 Deferred income tax benefit (531) (1,833) Gain on sale of facility (7,148) - Charges in operating assets and liabilities: (71,746) (1,796) Trade receivables, net (12,796) (1,424) Inventories, net (42,436) (17,966) Charges in operating assets and liabilities: (30,604) (6333) Charges in other operating assets and liabilities (30,604) (6333) Charges in other operating assets and liabilities (30,604) (6333) Net cash (used in) provided by operating activities (2,657) 40,402 Cash flows from investing activities: (11,097) (11,709) Purchases of fixed assets (11,097) (11,709) Proceeds from sale of facility 9,034 - Acquisitions, net of cash received (50,954) - <	Net income	\$	29,042	\$ 41,487		
Stock-based compensation expense5,5955,793Non-cash interest expense1,1201,000Loss on short term investments14,719Deferend income tax benefit(591)(1,433Gain on sale of facility(7,148)Changes in operating assets and liabilities:(7,148)Trade receivables, net(17,966)(1,424Inventories, net(42,436)(17,966)Accounts payable(81,836)(81,00Customer advances and biblitigs(30,004)(6,333Net cash (used in) provided by operating activities(2,657)(40,473)Purchases of fixed assets(11,097)(11,706)Purchases of fixed assets(11,097)(11,706)Porceeds from sale of facility9,034Acquisitions, net of cash received(50,954)Acquisitions, net or cash received(54,075)(11,007)Porceeds from sale of facility(9,034)Payments under term credit facilities and other(99,000)(257,152)Proceeds from insung activities(11,007)(11,706)Proceeds from insung on revolving credit facilities and other(99,000)(257,152)Proceeds from insung activities(11,007)(11,706)Proceeds from insung activities(11,007)(11,706)Proceeds from insung activities(11,007)(11,706)Proceeds from insung activities(11,007)(11,706)Proceeds from insung activities(11,007)(11,706)Procee	Adjustments to reconcile net income to net cash (used in) provided by operating activities:					
Non-cash interest expense1,1201,000Loss on short term investments14,719—Deferred income tax benefit(591)(1,833)Gain on sale of facility(7,148)—Changes in operating assets and liabilities:(17,896)(1,422)I'rventories, net(17,896)(1,422)I'rventories, net(18,836)(8,100)Custome avalances and billings in excess of costs incurred(27,391)(4,492)Changes in operating assets and liabilities(30,604)(6,333)Net cash (used in) provided by operating activities(11,097)(11,700)Cash flows from investing activities:(11,097)(11,700)Purchases of fixed assets(11,097)(11,700)Purchases of fuxed assets(10,073)(11,700)Purchases of fuxed assets(10,073)(11,700)Purchases, net(10,08)—Vet cash used in investing activities(50,964)—Payments under term credit facility(18,705)(11,700)Proceeds from barrowings on revolving credit facilities and other(19,800)(257,152)Proceeds from borrowings on revolving credit facilities and other(99,600)(257,152)Proceeds from borrowings on revolving credit facilities and other <td>Depreciation, amortization and impairment charges</td> <td></td> <td>36,987</td> <td>31,972</td>	Depreciation, amortization and impairment charges		36,987	31,972		
Loss on short term investments 14,719 Deferred income tax benefit (591) (1,833) Gain on sale of facility (7,148) Changes in operating assets and liabilities: (17,896) (1,424) Inventories, net (17,896) (1,424) Inventories, net (17,896) (1,424) Changes in operating assets and liabilities (42,436) (17,966) Accounts payable (18,836) (8,100) Customer advances and billings in excess of costs incurred (2,657) (40,00) Changes in other operating assets and liabilities (2,657) (40,00) Cash flows from investing activities (2,657) (40,00) Purchases of fixed assets (11,097) (11,097) Purchases of fixed assets (10,049) Acquisitions, net of cash received (50,964) Sale of business, net (1,048) Payments under term credit facility (18,750) (9,373) Proceeds from financing activities (11,709 (11,709) Payments under term credit	Stock-based compensation expense		5,595	5,799		
Deferred income tax benefit (591) (1.833 Gain on sale of facility (7,148) Changes in operating assets and liabilities: (17,996) (1,424) Inventories, net (17,996) (1,424) Inventories, net (42,436) (17,996) Accounts payable (18,836) (8,104) Customer advances and biblings in excess of costs incurred 27,391 (4,192) Changes in other operating assets and liabilities (30,604) (6.333) Net cash (used in) provided by operating activities (2,657) 40,007 Cash flows from investing activities (11,097) (11,702) Purchases of fixed assets (11,097) (11,702) Purchases of fixed assets (10,494) Acquisitions, net of cash received (50,964) Sale of business, net (10,493) Payments under term credit facility (9,372) (11,702) Proceeds from binorowings on revolving credit facilities and other (19,600) (257,153) Proceeds from binorowings on revolving credit facilities and other (99,600) <td>Non-cash interest expense</td> <td></td> <td>1,120</td> <td>1,003</td>	Non-cash interest expense		1,120	1,003		
Gain on sale of facility (7,148) (7,148) Changes in operating assets and liabilities: (17,896) (1,424) Trade receivables, net (17,896) (1,424) Inventories, net (42,436) (17,966) Accounts payable (18,836) (8,104) Customer advances and billings in excess of costs incurred (27,391) (4,492) Changes in other operating assets and liabilities (30,604) (6,333) Net cash (used in) provided by operating activities (2,657) 40,402 Purchases of fixed assets (11,097) (11,709) Proceeds from sale of facility 9,034 - Acquisitions, net of cality 9,034 - Sale of business, net (10,488) - Net cash used in investing activities (11,709) (11,709) Payments under term credit facility (18,750) (9,372) Phorceeds from borrowings on revolving credit facilities and other (19,9600) (257,152) Proceeds from insuance of common stock, net 2,555 2,244 Other (690) (2,490) (24,90	Loss on short term investments		14,719	_		
Changes in operating assets and liabilities:Trade receivables, net(17,896)(1,420)Inventories, net(42,436)(17,966)Accounts payable(18,836)(8,100)Customer advances and billings in excess of costs incurred27,391(4,192)Changes in other operating assets and liabilities(30,604)(6,338)Net cash (used in) provided by operating activities(2,657)40,004)Purchases of fixed assets(11,097)(11,709)Proceeds from sale of facility9,034Acquisitions, net of cash received(50,964)Sale of business, net(1,048)Net cash used in investing activities:(11,007)(11,709)Proceeds from sale of facility(10,475)(11,709)Proceeds from sale of facility(10,475)(11,709)Proceeds from investing activities:(10,475)(11,709)Proceeds from investing activities:(10,475)(11,709)Proceeds from borrowings on revolving credit facilities and other(17,386)(21,948)Proceeds from issuance of common stock, net(2,565)(2,244)Other(6900)(2,57,155)(2,440)Net cash provided by (used in) financing activities(5,648)(4,059)Increase (decrease) in Cash and cash equivalents(5,648)(4,059)Increase (decrease) in Cash and cash equivalents(6,327)(13,890)Cash and cash equivalents, beginning of period(26,019)(22,17,30)	Deferred income tax benefit		(591)	(1,833		
Trade receivables, net (17,896) (14,242) Inventories, net (42,436) (17,966) Accounts payable (18,836) (8,100) Customer advances and billings in excess of costs incurred 27,391 (4,192) Changes in other operating assets and liabilities (30,604) (6,332) Net cash (used in) provided by operating activities (2,657) (40,402) Purchases of fixed assets (11,097) (11,700) Proceeds from sale of facility 9,034 Acquisitions, net of cash received (50,964) Sale of business, net (10,409) Net cash lused in investing activities (11,097) (11,700) Proceeds from share of cash received (50,964) Sale of busines, net (10,409) Sale of busines, net (11,970) (11,700) Proceeds from borrowings on revolving credit facilities and other (11,973) (11,703) Proceeds from borrowings on revolving credit facilities and other 173,886 219,483 Repayments of borrowings on revolving credit facilities and other (13,800) (22,474) Other	Gain on sale of facility		(7,148)	_		
Inventories, net(42,436)(17,963)Accounts payable(18,836)(8,104)Customer advances and billings in excess of costs incurred27,391(4,192)Changes in other operating assets and liabilities(30,604)(6,338)Net cash (used in) provided by operating activities(2,657)40,007Cash flows from investing activities:(11,097)(11,709)Purchases of fixed assets(11,097)(11,709)Proceeds from sale of facility9,034	Changes in operating assets and liabilities:					
Accounts payable(18,836)(18,1436)Customer advances and billings in excess of costs incurred27,391(4,192Changes in other operating assets and liabilities(30,604)(6,338Net cash (used in) provided by operating activities(2,657)40,408Cash flows from investing activities:(11,097)(11,709Purchases of fixed assets(11,097)(11,709Proceeds from sale of facility9,034Acquisitions, net of cash received(50,964)Sale of business, net(1,048)Net cash used in investing activities:(11,048)Payments under term credit facilities and other(18,750)(11,709Proceeds from borrowings on revolving credit facilities and other(99,600)(257,157Proceeds from insuance of common stock, net2,5652,244Other(6900)(24,905(2,490Net cash provided by (used in) financing activities5,6484,699Increase (decrease) in Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890Cash and cash equi	Trade receivables, net		(17,896)	(1,428		
Customer advances and billings in excess of costs incurred27,391(4,192)Changes in other operating assets and liabilities(30,604)(6,330)Net cash (used in) provided by operating activities(2,657)40,400Cash flows from investing activities:(11,097)(11,709)Purchases of fixed assets(11,097)(11,709)Proceeds from sale of facility9,034Acquisitions, net of cash received(50,964)Sale of business, net(10,489)Net cash used in investing activities(11,709)(11,709)Proceeds from financing activities(11,048)Payments under term credit facility(11,709)(11,709)Proceeds from borrowings on revolving credit facilities and other(18,750)(11,709)Proceeds from borrowings on revolving credit facilities and other(99,600)(25,71,52)Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490)Net cash provided by (used in) financing activities5,6484,699Increase (decrease) in Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890)Cash and cash equivalents6,327 <td>Inventories, net</td> <td></td> <td>(42,436)</td> <td>(17,961</td>	Inventories, net		(42,436)	(17,961		
Changes in other operating assets and liabilities(30,604)(6,333Net cash (used in) provided by operating activities(2,657)40,400Cash flows from investing activities:(11,097)(11,709)Purchases of fixed assets(11,097)(11,709)Proceeds from sale of facility9,034-Acquisitions, net of cash received(50,964)-Sale of business, net(10,488)-Net cash used in investing activities(11,709)(11,709)Payments under term credit facility(18,750)(11,709)Proceeds from borrowings on revolving credit facilities and other(18,750)(9,379)Proceeds from borrowings on revolving credit facilities and other(199,600)(257,153)Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490)Net cash provided by (used in) financing activities5,6484,6699Increase (decrease) in Cash and cash equivalents5,6484,6699Increase (decrease) in Cash and cash equivalents6,327(13,890)Cash and cash	Accounts payable		(18,836)	(8,104		
Net cash (used in) provided by operating activities(2,657)40,400Cash flows from investing activities:(11,097)(11,709)Purchases of fixed assets(11,097)(11,709)Proceeds from sale of facility9,034Acquisitions, net of cash received(50,964)Sale of business, net(10,48)Net cash used in investing activities(54,075)(11,709)Cash flows from financing activities:(18,750)(9,375)Payments under term credit facilities and other(18,750)(9,375)Proceeds from borrowings on revolving credit facilities and other(99,600)(257,155)Proceeds from issuance of common stock, net2,5652,244Other(690)(24,900)Net cash provided by (used in) financing activities57,411(47,285)Effect of foreign exchange rates on Cash and cash equivalents5,6484,6990Increase (decrease) in Cash and cash equivalents6,327(13,890)Cash and cash equivalents6,327(13,890)Cash and cash equivalents262,019221,730	Customer advances and billings in excess of costs incurred		27,391	(4,192		
Cash flows from investing activities:Purchases of fixed assets(11,097)(11,700Proceeds from sale of facility9,034-Acquisitions, net of cash received(50,964)-Sale of business, net(1,048)-Net cash used in investing activities(54,075)(11,700Payments under term credit facilities and other(18,750)(9,375)Proceeds from borrowings on revolving credit facilities and other(99,600)(257,155)Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490)Net cash provided by (used in) financing activities5,6484,669Increase (decrease) in Cash and cash equivalents5,6484,669Cash and cash equivalents, beginning of period262,019221,730	Changes in other operating assets and liabilities		(30,604)	(6,338		
Purchases of fixed assets(11,097)(11,709)Proceeds from sale of facility9,034-Acquisitions, net of cash received(50,964)-Sale of business, net(1,048)-Net cash used in investing activities(54,075)(11,709)Cash flows from financing activities:(18,750)(9,375)Payments under term credit facilities and other173,886219,489Repayments of borrowings on revolving credit facilities and other(99,600)(257,155)Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490)Net cash provided by (used in) financing activities5,6484,669Increase (decrease) in Cash and cash equivalents5,6484,669Cash and cash equivalents, beginning of period262,019221,730	Net cash (used in) provided by operating activities		(2,657)	40,405		
Proceeds from sale of facility9,0349Acquisitions, net of cash received(50,964)-Sale of business, net(1,048)-Net cash used in investing activities(54,075)(11,705)Cash flows from financing activities:(18,750)(9,375)Payments under term credit facility(18,750)(9,375)Proceeds from borrowings on revolving credit facilities and other(18,750)(9,375)Proceeds from borrowings on revolving credit facilities and other(18,750)(9,375)Proceeds from issuance of common stock, net(257,155)(2,244)Other(690)(2,490)Net cash provided by (used in) financing activities57,411(47,285)Effect of foreign exchange rates on Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890)Cash equivalents, beginning of period262,019221,730	Cash flows from investing activities:					
Acquisitions, net of cash received(50,964)Sale of business, net(1,048)Net cash used in investing activities(54,075)(11,709)Cash flows from financing activities:(18,750)(9,379)Payments under term credit facility(18,750)(9,379)Proceeds from borrowings on revolving credit facilities and other173,886219,489Repayments of borrowings on revolving credit facilities and other(99,600)(257,155)Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490)Net cash provided by (used in) financing activities57,411(47,285)Effect of foreign exchange rates on Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890)Cash and cash equivalents, beginning of period262,019221,730	Purchases of fixed assets		(11,097)	(11,709		
Sale of business, net(1,048)Net cash used in investing activities(54,075)(11,709)Cash flows from financing activities:(18,750)(9,379)Payments under term credit facility(18,750)(9,379)Proceeds from borrowings on revolving credit facilities and other173,886219,488Repayments of borrowings on revolving credit facilities and other(99,600)(257,153)Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490)Net cash provided by (used in) financing activities57,411(47,285)Effect of foreign exchange rates on Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890)Cash and cash equivalents, beginning of period262,019221,730	Proceeds from sale of facility		9,034	_		
Net cash used in investing activities(11,70)Cash flows from financing activities:(11,70)Payments under term credit facility(18,750)Proceeds from borrowings on revolving credit facilities and other173,886Repayments of borrowings on revolving credit facilities and other(99,600)Proceeds from issuance of common stock, net2,565Other(690)Net cash provided by (used in) financing activities57,411Effect of foreign exchange rates on Cash and cash equivalents5,648Increase (decrease) in Cash and cash equivalents6,327Cash and cash equivalents, beginning of period262,019221,730	Acquisitions, net of cash received		(50,964)	_		
Cash flows from financing activities:(18,750)(9,375)Payments under term credit facility(18,750)(9,375)Proceeds from borrowings on revolving credit facilities and other173,886219,485Repayments of borrowings on revolving credit facilities and other(99,600)(257,155)Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490)Net cash provided by (used in) financing activities57,411(47,285)Effect of foreign exchange rates on Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890)Cash and cash equivalents, beginning of period262,019221,730	Sale of business, net		(1,048)	_		
Payments under term credit facility(18,750)(9,375)Proceeds from borrowings on revolving credit facilities and other173,886219,485Repayments of borrowings on revolving credit facilities and other(99,600)(257,155)Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490)Net cash provided by (used in) financing activities57,411(47,285)Effect of foreign exchange rates on Cash and cash equivalents5,6484,609Increase (decrease) in Cash and cash equivalents6,327(13,890)Cash and cash equivalents, beginning of period262,019221,730	Net cash used in investing activities		(54,075)	(11,709		
Proceeds from borrowings on revolving credit facilities and other173,886219,485Repayments of borrowings on revolving credit facilities and other(99,600)(257,157Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490Net cash provided by (used in) financing activities57,411(47,287Effect of foreign exchange rates on Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890Cash and cash equivalents, beginning of period262,019221,730	Cash flows from financing activities:					
Repayments of borrowings on revolving credit facilities and other(99,600)(257,152Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490Net cash provided by (used in) financing activities57,411(47,285Effect of foreign exchange rates on Cash and cash equivalents5,6484,695Increase (decrease) in Cash and cash equivalents6,327(13,890Cash and cash equivalents, beginning of period262,019221,735	Payments under term credit facility		(18,750)	(9,375		
Proceeds from issuance of common stock, net2,5652,244Other(690)(2,490Net cash provided by (used in) financing activities57,411(47,285Effect of foreign exchange rates on Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890Cash and cash equivalents, beginning of period262,019221,730	Proceeds from borrowings on revolving credit facilities and other		173,886	219,489		
Other(690)(2,49)Net cash provided by (used in) financing activities57,411(47,28)Effect of foreign exchange rates on Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890Cash and cash equivalents, beginning of period262,019221,730	Repayments of borrowings on revolving credit facilities and other		(99,600)	(257,153		
Net cash provided by (used in) financing activities57,411(47,285Effect of foreign exchange rates on Cash and cash equivalents5,6484,695Increase (decrease) in Cash and cash equivalents6,327(13,890Cash and cash equivalents, beginning of period262,019221,730	Proceeds from issuance of common stock, net		2,565	2,244		
Effect of foreign exchange rates on Cash and cash equivalents5,6484,699Increase (decrease) in Cash and cash equivalents6,327(13,890Cash and cash equivalents, beginning of period262,019221,730	Other		(690)	(2,490		
Increase (decrease) in Cash and cash equivalents6,327(13,890Cash and cash equivalents, beginning of period262,019221,730	Net cash provided by (used in) financing activities		57,411	(47,285		
Cash and cash equivalents, beginning of period 262,019 221,730	Effect of foreign exchange rates on Cash and cash equivalents		5,648	4,699		
	Increase (decrease) in Cash and cash equivalents		6,327	(13,890		
Cash and cash equivalents, end of period \$ 268,346 \$ 207,840	Cash and cash equivalents, beginning of period		262,019	221,730		
	Cash and cash equivalents, end of period	\$	268,346	\$ 207,840		